Long-Term Efficacy of Risk-Directed, De-Escalated Post-Operative Adjuvant Therapy for Surgically Resected Locally Advanced, Human Papillomavirus-Positive Oropharynx Squamous-Cell Carcinoma (HPV+ OPSCC): A Non-Randomized, Multi-Arm Phase 2 Trial

Wade L. Thorstad, D. Adkins, Peter Oppelt et al.|International Journal of Radiation Oncology*Biology*Physics|2024

Cited by 5